Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients Who Have Had Surgery to Remove Benign Colorectal Polyps - Related Studies

Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients Who Have Had Surgery to Remove Benign Colorectal Polyps

This study is ongoing, but not recruiting participants.

Study NCT00005882. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Colorectal Cancer

2	Additional conditions recognized in this trial
		Colorectal Neoplasms

3	More general conditions related to this trial
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Rectal Diseases

4	Interventions listed in this trial
		eflornithine
		sulindac

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antineoplastic Agents
		Antiparasitic Agents
		Antiprotozoal Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses
		Trypanocidal Agents

6	Sponsors listed in this trial
		Chao Family Comprehensive Cancer Center
		National Cancer Institute (NCI)